Ionis’ drug, called sapablursen, is currently being tested in a Phase 2 trial in people with polycythemia vera.

Carlsbad’s Ionis Pharmaceuticals struck a deal worth up to $940 million with Japan-based Ono Pharmaceutical for its medicine ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Ono Pharmaceutical Co., Ltd (Ono), today announced that the two companies have entered into a license a ...

Ionis Pharmaceuticals IONS signed a license agreement with Japan-based Ono Pharmaceutical. Per the terms, Ono has acquired exclusive global rights from IONS to develop and market sapablursen, an ...

Ionis Pharmaceuticals ... an investigational RNA-targeted medicine for polycythemia vera (PV), a rare and potentially life-threatening hematologic disease. Sapablursen is currently being evaluated ...

Ionis will receive $280M upfront from Ono ... Sapablursen, an investigational RNA therapy for polycythemia vera, is in a fully enrolled Phase 2 trial. How to Spot the Market Bottom: Matt Maley ...

Ionis is also eligible to earn royalties in ... president and COO, Ono. About Polycythemia Vera (PV) PV is a rare and potentially life-threatening hematologic disease characterized by the ...

Ionis Pharmaceuticals Inc (NASDAQ:IONS) and Ono Pharmaceutical Co., Ltd entered into a license agreement in which Ono obtains exclusive global rights for the development and commercialization of ...